Biocrucible

Sapphiros is a private, commercial-stage diagnostics company positioned to disrupt global health testing through scalable, low-cost technology platforms. The company has secured significant strategic partnerships, including a major supply agreement with Roche and a development contract with BARDA, validating its manufacturing capability and product pipeline. With a leadership team boasting deep industry experience and a UK-based facility capable of producing five billion units annually, Sapphiros aims to redefine everyday health management by moving testing out of labs and into consumers' hands.

Extreme Volume Manufacturing (EVM) for diagnostics; proprietary automated facility with 5B unit capacity. Platform spans lateral flow assays (antigen) and future molecular point-of-care tests, with a focus on low-cost, user-friendly, and digitally connected design.

Sapphiros competes in the broad point-of-care and rapid diagnostics market against giants like Abbott, QuidelOrtho, and Roche itself, as well as numerous smaller innovators. Its primary differentiation is its stated focus on achieving the lowest cost at extreme volume through proprietary manufacturing, rather than solely on assay innovation. This positions it as a potential bulk supplier to governments and partners, competing on scale and cost with manufacturers in Asia, while its digital and future molecular aims pit it against companies like Cue Health and Lucira.